Sanguistat

NIH to Feinstein: Stick out that chest (bioelectrically)

By GREGORY ZELLER // With new treatments for obesity, heart failure and a host of other conditions in sight, a Feinstein Institute researcher will zero in on specific abdominal targets in a new “precision bioelectronic medicine” study. North Shore University Hospital and Long Island Jewish Medical Center Chief of Gastroenterology Larry Miller, who also directs the Gastroenterology Laboratory at the Feinstein Institute for Medical Research, has received a $1.4 million National Institutes of Health grant…


No. 324: Vikings on Mars, FSC on the job, Sanguistat on the move, and why Freeport is happy to be on the outs

Well done: Very impressive, intrepid reader – you’ve made it to the end of another productive workweek, and earned yourself another glorious weekend. It’s July 20 out there, and if you said “knight to king 4,” good move, since today is of course International Chess Day, commemorating the launch of the World Chess Federation on this date in 1924. The Eagle has landed: Today also marks the 49th anniversary of one of mankind’s greatest scientific…


Nerve-stim startup Sanguistat shuffles its deck

By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized global leaders in the burgeoning field of biolelectronic medicine. Sanguistat Inc., a 2016 clinical-stage medical-device startup, has named Feinstein Institute President and CEO Kevin Tracey as chairman of its Scientific Advisory Board, a role that will leverage the pioneer’s decades of groundbreaking bioelectronics research. The…


Nerves of steel: Sanguistat stimulator steps up

By GREGORY ZELLER // The world’s leading cause of maternal deaths is the target of new clinical trials for a trailblazing bioelectronic medical device. The Neural Tourniquet, an electronic nerve-stimulation technology licensed to Sanguistat Inc. by the Feinstein Institute for Medical Research, is seeing action against postpartum hemorrhage in new clinical trials underway at Feinstein, the research arm of the Northwell Health system. Sanguistat, a 2016 clinical-stage medical device spinoff founded by Feinstein Vice President…


Feinstein’s Tracey to head bioelectronics summit

Feinstein Institute chief and global bioelectronics pioneer Kevin Tracey will headline a September New York Academy of Science conference on bioelectronic medicine. Tracey, Feinstein’s president and CEO and the brains behind bioelectronic startup Sanguistat, will share keynote duties with Peder Olofsson, a longtime Feinstein Institute researcher and Wallenberg Academy Fellow at the Karolinska Institutet. The two will headline Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms, presented by the Feinstein Institute, the Royal…


Feinstein launching Neural Tourniquet as newco

By GREGORY ZELLER // Meet Sanguistat, the corporate face of the latest technology spinning out of Northwell Health’s Feinstein Institute for Medical Research. For now, Sanguistat is not an Inc. or LLC. But it does have co-founders – Feinstein vice president Christopher Czura, who will be the new company’s chief scientific officer, and Jared Huston, a medical doctor and Feinstein researcher who will serve as chief medical officer. Czura and Huston are also listed as…